Starling Oncology, Inc.
STLN- Exchange
- Nasdaq
- Industry
- Services-Offices & Clinics of Doctors of Medicine
- SEC CIK
- 0001799191
In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; 119 institutions reported holding it in 13F filings for Q2 2026, worth $217.6M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Starling Oncology, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 79 | 108 | +29 |
| Shares | 31.9M | 34.7M | +2.73M (+8.6%) |
| Value | $65.5M | $121.0M | +$55.5M (+84.8%) |
New holders (35)
Institutions that held Starling Oncology, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (6)
Institutions that held Starling Oncology, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Portolan Capital Management, LLC | 221,512 | $454.1K |
| Citizens Financial Group Inc | 119,000 | $243.9K |
| Susquehanna International Group, LLP | 113,676 | $233.0K |
| Saba Capital Management, L.P. | 94,264 | $193.2K |
| XTX Topco Ltd | 49,443 | $101.4K |
| Hudson Bay Capital Management LP | 15,200 | $31.2K |